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Abstract Though among U.S. women endometrial cancer is the most common invasive gynecological 
cancer, it has a relatively favorable prognosis. From 1986-1990, approximately 19% of U.S. Surveillance, 
Epidemiology and End Results (SEER) Program cases were diagnosed in women less than 55 years of 
age; however, the age-specific incidence (per 100,000) peaked at 70-74 years (110.7), which was 2.85 
times the rate reported at 50-54 years (38.9). The incidence under 50 years was 2.19 times higher in U.S. 
White compared with US. Black women; for uterine corpus cancers diagnosed at 50 years and older, 
the ratio declined but continued to be elevated in Whites (1.46). In contrast, average annual age-adjusted 
mortality (per 100,000) from 1986-1990 for uterine corpus cancer (1970 U.S. standard) was almost twice 
as high in U.S. Black women (6.0) as in U.S. White women (3.3). The determinants of age-specific 
elevated risks in mortality, in contrast to the lesser age-specific risks in incidence experienced by U.S. 
Black women compared with U.S. White women, may be explored with respect to socioeconomic and 
cultural factors that influence the distribution of epidemiologic risk factors such as reproductive history, 
choice of contraception methods, hormone replacement therapy, obesity, and dietary factors; age-specific 
prevalence of hysterectomy for other gynecological conditions; quality of medical care and surveillance 
practices; genetic factors influencing susceptibility; and tumor-associated biological factors. The majority 
of risk factors and medical conditions associated with endometrial cancer are related directly or indi- 
rectly to the levels and metabolic effects of the reproductive hormones, namely estrogens and proges- 
togens. The molecular, genetic, and epidemiologic characterization of endometrial cancer is attempting 
to delineate the multiple steps in the natural history of estrogen-induced or estrogen-responsive neo- 
plasms. 0 1995 Wiley-Liss, Inc. 
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Carcinoma of the uterine corpus is the most 
common invasive gynecologic cancer in the U.S. 
In US .  White women during 1973-1990, the age- 
adjusted incidence (per 100,000) for cancer of the 
uterine corpus peaked around 1974-1976 (32.91, 
and then declined significantly, so that by 1990, 
the incidence was 22.7, or about 30% less than 
the incidence in the mid-1970s [I]. During the 
same time period, age-adjusted mortality de- 
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clined by 42% in U.S. White women under 50 
years, and by 23% in women 50 years and over. 
Age-specific incidence rates increased more rap- 
idly in women under 50 years, a t  least doubling 
in each five-year age group after age 35 years, 
than in women 50 years and over, where the rate 
of increase in each five-year age group between 
50-74 years was only 27%; after age 75 years, the 
incidence rates declined slightly in White and 
Black women (Fig. 1). During 1986-1990, approx- 
imately 19% of U.S. Surveillance, Epidemiology 
and End Results (SEER) cases were diagnosed in 
women < 55 years of age; the age-specific inci- 
dence peaked at  70-74 years (110.7), which was 
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Fig. 1. Age-specific incidence and mortality for cancer of 
the uterine corpus, by race, U.S. SEER, 1986-1990. 
The incidence of uterine corpus cancer diag- 
nosed under age 50 years was 2.2 times higher in 
U.S. White compared with Black women; for 
uterine corpus cancer diagnosed in women 50 
years and over, the incidence or risk in U.S. 
Whites relative to U.S. Blacks declined, but re- 
mained elevated (1.5). During the period be- 
tween 1973-1990, the age-adjusted incidence 
rates in U.S. Black women under age 50 years 
decreased by 33.7%, but increased slightly by 
16.4% over age 50. 
In contrast, average annual age-adjusted mor- 
tality (per 100,000) in 1986-1990 for uterine cor- 
pus cancer (including deaths certified as "uterus, 
not otherwise specified") was almost twice as 
high in U.S. Blacks (6.0) than in U.S. Whites (3.3). 
However, between 1973-1990, mortality declined 
in women < 50 years by about 62% in Black 
women and 42% in White women; in women 50 
years of age and older, mortality declined by 
17% in Black and 23% in White women. The age- 
specific mortality rates (1986-1990) were consis- 
tently higher in U.S. Black women compared 
with U.S. White women, particularly after age 50 
years (Fig. 1). 
US. BLACK-WHITE DIFFERENCES: 
NURTURE OR NATURE? 
A pattern for cancer of the uterine corpus, at 
least since the early 1970s in the U.S., has been 
elevated age-specific incidence rates in Whites 
compared with Blacks, but elevated age-specific 
mortality rates and case fatality rates in Blacks 
who developed invasive disease. The ratio of 
age-adjusted mortality to age-adjusted incidence 
for uterine corpus cancer was 0.41 in U.S. Black 
women and 0.15 in U.S. White women, suggest- 
ing that the likelihood of a case fatality for each 
incident case in Black women was at least twice 
that in White women. Excessive mortality experi- 
enced by U.S. Blacks is being explored with re- 
spect to behavioral and medical care characteris- 
tics correlated with socioeconomic status, the 
distribution of epidemiologic risk factors and 
their association with causal mechanisms, tumor- 
associated biological factors, and genetic factors 
influencing susceptibility or interacting with sex 
steroid hormone metabolism. Socioeconomic sta- 
tus and cultural factors which are correlated with 
race may influence access to or quality of medi- 





cal care; knowledge, attitudes and behavior with 
respect to screening and early detection practices; 
choice of contraception methods and use of post- 
menopausal hormone replacement therapy; and 
the distribution of other life-style risk factors 
associated with endometrial adenocarcinoma 
incidence (92% of cancers of the uterine corpus) 
and/or survival rates. 
White women in the SEER population diag- 
nosed with uterine corpus cancer in 1983-1989 
had a five-year relative survival rate in all stages 
of 93.2% under age 50 years and 83.6% for age 
50 years and older. The comparable five-year 
relative survival in Black women was 80.6% and 
51.1%, respectively. The proportion with local- 
ized disease was 23% higher (75% compared 
with 52%) in Whites, who exhibited significantly 
better five-year relative survival than Blacks after 
controlling for stage and grade of differentiation 
(Table I). Black women presented with more ad- 
vanced stages of poorly differentiated tumors 
compared with White women. Most of the de- 
crease in age-adjusted incidence in Whites for 
uterine corpus cancer since the late 1970s was for 
adenocarcinomas, including sub-groups classified 
with squamous metaplasia; from 1973-1987, the 
age-adjusted incidence of adenocarcinoma of the 
endometrium (per 100,000) in Whites decreased 
from 28.7 to 21.1, but remained relatively stable 
in Blacks (11.3 to 10.6). Adenocarcinomas ac- 
counted for more than 90% of cancers of the 
uterine corpus in Whites, in contrast to 78% in 
Blacks. In contrast, sarcomas (e.g., leiomyosar- 
coma, endometrial stromal sarcoma) and mixed 
Z t  99.2 93.9 91.6 61.8 72.5 40.9 48.9 _- 
97.0 81.5 89.1 66.7 63.0 40.9 43.7 __ 
97.7 81.5 86.1 66.7 59.4 22.7 39.3 __ 
98.3 86.7 90.6 68.5 59.5 35.2 45.2 34.3 
Miillerian and mesodermal tumors, generally of 
poor prognosis, were relatively more frequent in 
Blacks (19%) than in Whites (54%) [21. Clear 
cell, serous, and adenosquamous (other uncom- 
mon subtypes of carcinoma) were associated 
with poorer prognosis, higher grade of differenti- 
ation, occurred generally in older women, and 
have not varied in incidence over time or been 




Women with elevated endogenous estrogen 
levels, as in obesity, the Stein-Leventhal syn- 
drome, and estrogen-secreting tumors of the 
ovary, are at increased risk for endometrial can- 
cer and its morphologic precursor condition, 
atypical endometrial hyperplasia [31. Estradiol is 
normally the most potent endogenous estrogen, 
but estrone assumes significance in postmeno- 
pausal women. Estrogens increase the mitotic 
rate of endometrial cells. Progestins oppose this 
action by decreasing the concentration of estro- 
gen receptors, and by causing differentiation of 
the endometrial cells to a secretory state [41. 
OBESITY 
Obesity is a chronic metabolic disorder charac- 
terized by an excess of body fat. The increased 
risk of endometrial cancer is associated with in- 
creased relative weight (% excess weight cor- 
TABLE I. Five-Year Relative Survival (%) by Race, Year of Diagnosis, and Grade 
of Differentiation for Uterine Corpus Cancer in Women 50 Years and Over 
Grade of Differentiation” 
I I1 I11 IV 
Year of Diagnosis B+ W B W B W B 
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rected for age, sex, and frame), body mass index 
(Quetelet's BMI = weight/heighi?), waist-to-thigh 
circumference ratio (WTR), or waist-to-hip cir- 
cumference ratio (WHR) [5-81. Cancer of the en- 
dometrium was the site most strongly associated 
with obesity in the American Cancer Society Pro- 
spective Study I, with women who were 40% 
overweight exhibiting more than a four-fold in- 
crease in mortality [9]. The relative risk of endo- 
metrial cancer in relation to measures of extreme 
obesity (e.g., 2 130% above the standard) and an 
anthropometric pattern of abdominal (visceral 
and subcutaneous) fat distribution may range 
between 2-5 times the risk in a referent or con- 
trol group 110-121. Whereas the lifetime risk of 
being diagnosed with endometrial cancer in the 
U.S. is 2.7%, the cumulative risk increases to 
about 9-10% in extremely obese women (BMI 
2 30). Based on estimates of relative risk and 
prevalence of obesity in U.S. women 45-64 years 
of age, excessive weight (standardized for height) 
and a central or android pattern of fat distribu- 
tion may account for 17% to 46% of endometrial 
cancer incidence in postmenopausal women 
(Table 11). 
Obesity may increase the risk of endometrial 
cancer because of the increased frequency of an- 
ovulatory cycles in premenopausal women and 
by altering estrogen and androgen metabolism in 
postmenopausal women (Table 111). With the ces- 
sation of ovulation at the onset of menopause, 
estrogen and androgen metabolism shifts from 
the ovary to the adrenal and adipocytes in sub- 
cutaneous and visceral tissues. Obesity, espe- 
cially abdominal adiposity, increases circulating 
estrogen levels by enhancing the availability of 
androstenedione from the adrenal and the effi- 
ciency of its metabolic conversion or aromatiza- 
tion to estrone and estradiol, and by decreasing 
the level and binding of sex hormone-binding 
TABLE 11. Summary of Relative, Cumulative Lifetime (0-74 years)' 
and Population Attributable Risks of Endometrial Cancer in 
United States Obese* Women 
Risk Measure 
Relative risk 
Cumulative lifetime risk about 9-10% 
Population attributable risk 
(%I, 4 5 6 4  years 1746% 
+ The lifetime risk of being diagnosed in the U.S. general population is 2.73%; * Obe- 
sity is defined as Body Mass Index [wt (kg)/h? (m)] 2 30. The estimated prevalence 
in US. women, 45-64 years of age is approximately 21% [31]. 
2-5 times the risk in the referent population 
TABLE 111. Endocrine Changes in Obesity 
ovary 
Normal or increased total and free estradiol 
Normal or increased total and free estrone 
Decreased hydroxylation at the 2a and 17a positions of estradiol 
Adipose Tissue 
Increased conversion of androgen to estrogen 
Adrenal 
Increased androgens (testosterone, 5~-dihydrotestosterone, and dehydroepiandrosterone) 
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globulin with estrogen which results in the in- 
creased availability and biologic activity of free 
estrogens (and androgens) [13-151. There is a 
significantly positive correlation between in- 
creases in androgenic activity (k., plasma levels 
of free testosterone, dihydrotestosterone, andro- 
stenedione and dehydroepiandrosterone) and 
increasing WHR (or WTR). Increasing androgenic 
activity is a determinant of body fat distribution, 
and is associated with decreasing peripheral in- 
sulin sensitivity, abnormal glucose tolerance, and 




By the mid 1970s, a substantial number of 
postmenopausal women in the U.S. had been 
using conjugated estrogens of equine origin dur- 
ing the 1960s and early 1970s. During the 1970s, 
the incidence of endometrial cancer increased 
significantly among White women ages 50-64, 
despite the competing concurrent trend of in- 
A 
creasing hysterectomy rates for benign gyneco- 
logic diseases [17]. Following the declining trend 
of prescribing estrogen without progestin during 
the late 1 9 7 0 ~ ~  endometrial cancer incidence 
diminished (Fig. 2). A parallel increase in exoge- 
nous estrogen prescriptions and increasing inci- 
dence of endometrial cancer was also described 
in Denmark. More than 40 case-control and co- 
hort studies of ERT and endometrial cancer have 
been conducted in various high-usage and low- 
usage populations [18-201. 
In general, use of unopposed estrogens for 
one or more years was associated with relative 
risks ranging from 1.5 to 10.0. Odds ratios were 
generally higher in case-control studies that used 
controls with nongynecologic diseases rather 
than gynecologic (excluding cancer) diseases. 
Duration of use and cumulative dose were sig- 
nificantly associated with the strength of relative 
risk. Although most studies have recorded a 
higher level of risk in current users, persistent 
risks after discontinuation of ERT ranged from 
5-15 years. Most studies emphasized that exoge- 
nous factors affecting circulating estrogen levels 
Blacks 
10 
1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 
Year 
Fig. 2. Age-adjusted incidence per 100,000, in women 50 
years and older, for cancer of the uterine corpus, by race, 
US.  SEER, 1986-1990. 
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were correlated with endometrial cancers of low 
grade of differentiation, superficial invasion into 
the myometrium, and other favorable prognostic 
characteristics. 
Progesterone secretion during the luteal phase 
of the menstrual cycle modulates the mitotic ef- 
fects of estrogenic stimulation. During the late 
secretory phase prior to menstruation, progester- 
one secretion diminishes rapidly, and apoptotic 
bodies appear in association with the marked 
attenuation in expression of BCL-2 protein [211. 
Epidemiologic studies provide compelling evi- 
dence of the benefits of adding progestogen 
when initiating ERT; however, the chemopre- 
ventive potential of progestogen will be limited 
to estrogen-responsive neoplasms [22,23]. 
Oral Contraceptives (OCs) 
In the 1970s, an increased risk of endometrial 
cancer was reported in women using sequential 
OCs, with relatively high-dose estrogen followed 
by progesterone. For this reason, sequential OCs 
such as Oracon were removed from the market 
in the mid-1970s. In contrast, use of combination 
OCs was shown to decrease the risk of endome- 
trial cancer by about 50% when compared with 
non-users. The protective effect of OCs was evi- 
dent after a minimum of one to three years of 
use, was dose-related, and persisted for at least 
five years after cessation of use [24,25]. 
COMPARING RISK FACTORS FOR 
ENDOMETRIAL AND BREAST CARCINOMA 
Indigenous populations from countries at high 
or low risk of uterine corpus cancer tend to show 
similar levels of risk for breast cancer (Table IV). 
In addition, these patterns change with gradual 
acculturation after migration, so that after one or 
two generations, the incidence rates approximate 
the levels of risk manifested by the host country. 
TABLE IV. Comparison of Age-Standardized Incidence Rates, 
Selected Countries, Uterine Corpus and Breast Cancer, 1985 1321 
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Sweden 
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China, Shanghai 2.9 
India, Bombay 2.3 
Japan, Miyagi 3.2 
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Early age at menarche t 
Early age at natural (or surgical) menopause 
Late age at natural menopause 




excluding pregnancies, lactation-months, 
and/or duration of OC use 
Pregnancy 
Married, never pregnant 
Early age, first full-term pregnancy 
Multiple full-term pregnancies 
Late age (> 35 yr) first full-term pregnancy 
Late age (> 35 yr) last full-term pregnancy 
Cumulative number of lactating months 
Family History 
Organ-specific 
Multiple organ primary cancers: 









Obesity: Excess average weight, weight gain, 
andor central versus peripheral obesity 
Premenopausal women + -/0 
Postmenopausal women + + 
Estrogen/Progestin - +/? 
Oral Contraceptive Steroids 




Fat (total, saturated) 
Calories 












+ = Increased risk (above 1.0); ? = Insufficient or equivocal data, - = Decreased risk (below LO), 
** = Reduction in risk toward 1.0,O = No relationship established. 
A review and comparison of risk factors for can- 
cer of the endometrium and breast inferred from 
epidemiologic studies is helpful in formulating 
causal hypotheses [Table V]. The hypothesis of 
"unopposed estrogen" and the chemopreventive 
action of progestins is compelling for cancer of 
the endometrium in premenopausal and post- 
menopausal women [17]. Target tissues respon- 
sive to estrogens and progesterone contain high- 
affinity receptor proteins. An important differ- 
ence between breast and endometrium is the 
mechanism of action of progesterone and syn- 
thetic progestins. The antagonistic effects of pro- 
gestins on the stimulating effects of estrogens are 
evident in normal and neoplastic endometrial 
tissues. However, as suggested by epidemiologic 
investigations, progestins do not appear to have 
the same protective effect for breast cancer, and 
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may even be tumorigenic [26,27]. In the normal 
breast, mitotic activity of ductal and lobular epi- 
thelium increases during the luteal phase rather 
than the follicular phase of the menstrual cycle. 
A rational approach to the primary prevention of 
endometrial cancer would include adding pro- 
gestin to estrogen therapy and avoiding obesity. 
The relative protective effects demonstrated for 
regular physical activity and a prudent and bal- 
anced diet with a high intake of carotenoids and 
enriched with the antioxidative properties of 
green and yellow vegetables may be correlated 
with estrogen metabolism and body fat topogra- 
phy. It has been hypothesized that environmen- 
tal and genetic factors that either decrease 16 a- 
hydroxylation or increase 2 a-hydroxylation of 
estradiol may protect against endometrial cancer 
[28-301. 
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